NNZ-2591 (cyclo-L-glycyl-L-2-allylproline) has not yet been allocated a generic name.
NNZ-2566 was named Trofinetide, and accepted by the WHO as its International Non-proprietary Name (INN) in 2015 (during the Ph2 trial).
Conversely, Ph2 trials for NNZ-2591 are expected to be completed in 2024, with the Ph2 Phelan-McDermid results published in December 2023.
As NEU prepares its FDA Ph2 submission, it's time for NNZ-2591 to be assigned a generic name.
NNZ-2591 development & commercialisation, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.47 |
Change
-1.120(7.18%) |
Mkt cap ! $1.849B | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.40 | $14.40 | $9.160M | 624.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $14.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.55 | 1764 | 2 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |